Length of stay and mortality associated with febrile neutropenia among children with cancer

被引:108
作者
Basu, SK [1 ]
Fernandez, ID [1 ]
Fisher, SG [1 ]
Asselin, BL [1 ]
Lyman, GH [1 ]
机构
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
关键词
D O I
10.1200/JCO.2005.01.6378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of this study was to evaluate risk factors for longer length of stay (los) and mortality among hospitalized children with cancer who have febrile neutropenia. Methods This study involved analysis of longitudinal data from the University HealthSystem Consortium database from 1995 to 2002. All patients who were 21 years or younger, with diagnostic codes for both neoplastic disease and febrile neutropenia at discharge, were included. Results A total of 12,446 patients were identified for the study. The los was 5 days or less for 6,799 patients, and greater than 5 days for 5,647 patients. The mortality rate was 3%. On bivariate analysis, race, age, cancer type, and associated complications (bacteremia/sepsis, hypotension, pneumonia, and fungal infections) were significantly associated with longer length of stay and death. On multivariate analysis, age group, race, cancer type (acute myeloid leukemia, multiple cancers v acute lymphoblastic leukemia), and the complication variables were significantly associated with increased risk of longer los and death. Certain types of cancer (Hodgkin's disease, osteosarcoma/Ewing's sarcoma, rhabdomyosarcoma, compared with acute lymphoblastic leukemia) and year of discharge after 1995 were significantly associated with a reduced risk of longer length of stay and/or mortality. Conclusion Race, age group, year of discharge, associated complications, and cancer type were significantly associated with risk of longer los and mortality. These factors may potentially help in identifying high-risk patients who might benefit from targeted antibiotic therapy or prophylactic hematopoietic growth factor support.
引用
收藏
页码:7958 / 7966
页数:9
相关论文
共 31 条
[1]  
Aquino VM, 2000, CANCER, V88, P1710, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1710::AID-CNCR27>3.3.CO
[2]  
2-T
[3]  
Baorto EP, 2001, CANCER, V92, P909, DOI 10.1002/1097-0142(20010815)92:4<909::AID-CNCR1400>3.0.CO
[4]  
2-H
[5]   Influence of race and socioeconomic status on outcome of children treated for childhood acute lymphoblastic leukemia [J].
Bhatia, S .
CURRENT OPINION IN PEDIATRICS, 2004, 16 (01) :9-14
[6]   Racial and ethnic differences in survival of children with acute lymphoblastic leukemia [J].
Bhatia, S ;
Sather, HN ;
Heerema, NA ;
Trigg, ME ;
Gaynon, PS ;
Robison, LL .
BLOOD, 2002, 100 (06) :1957-1964
[7]   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].
Hughes, WT ;
Armstrong, D ;
Bodey, GP ;
Bow, EJ ;
Brown, AE ;
Calandra, T ;
Feld, R ;
Pizzo, PA ;
Rolston, KVI ;
Shenep, JL ;
Young, LS .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751
[8]   Infection risk factors in febrile, neutropenic children and adolescents [J].
Jones, GR ;
Konsler, GK ;
Dunaway, RP ;
Pusek, SN .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1996, 13 (03) :217-229
[9]   Low-risk prediction rule for pediatric oncology patients presenting with fever and neutropenia [J].
Klaassen, RJ ;
Goodman, TR ;
Pham, B ;
Doyle, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :1012-1019
[10]   The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients [J].
Klastersky, J ;
Paesmans, M ;
Rubenstein, EB ;
Boyer, M ;
Elting, L ;
Feld, R ;
Gallagher, J ;
Herrstedt, J ;
Rapoport, B ;
Rolston, K ;
Talcott, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :3038-3051